Physician profile
Nabil Aziz
NPI 1740375617
$17,471.53
in general payments reported to CMS, 2019-2025
63 companies · $944 in 2025
The $944 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,072 · 2020: $623 · 2021: $1,019 · 2022: $4,969 · 2023: $790 · 2024: $1,055 · 2025: $944.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,639 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,638.79 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $7,028.96 | 2019-2024 | Austedo Xr, Austedo |
| Acadia Pharmaceuticals INC | $3,906.87 | 2019-2024 | Nuplazid |
| Biogen, INC. | $956.83 | 2019-2025 | Tysabri, Vumerity, Plegridy |
| Abbvie INC. | $793.32 | 2021-2025 | Qulipta, Duopa, Ubrelvy |
| Genzyme Corporation | $365.97 | 2019-2025 | |
| Lilly USA, LLC | $288.51 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Amneal Pharmaceuticals LLC | $241.11 | 2019-2025 | Ongentys, Crexont, Rytary |
| Novartis Pharmaceuticals Corporation | $216.59 | 2019-2024 | |
| Genentech USA, INC. | $194.72 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Tg Therapeutics, INC. | $176.29 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $173.33 | 2020-2025 | Ingrezza, Ongentys |
| Mdd US Operations, LLC | $170.47 | 2019-2024 | Gocovri |
| Ucb, INC. | $167.56 | 2019-2024 | Nayzilam, Briviact |
| Lundbeck LLC | $166.58 | 2020-2025 | Vyepti |
| Sk Life Science, INC. | $162.25 | 2020-2025 |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nabil Aziz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.